Option chain shows key data for UCB's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for UCB.

UCB (OTC:UCBJY) Stock, Option Chain

UCB ADR

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

Jakarta,-,Sept,12,2024:,National,Health,Service,(nhs),England,Signboard

Biotech

Government

Large Cap

News

Eurozone

Health Care

General

AMGN

BIIB

DSNKY

GILD

RHHBY

UCBJF

UCBJY

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&amp;D investment and falling global competitiveness.

Pharmaceutical Firms Say UK Investment Is &#39;Unlikely&#39; Unless Payment Levy Is Adressed

Protect Your Skin

Europe-Based UCB&#39;s Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders

Biogen - logo

Analyst Color

Equities

Reiteration

Analyst Ratings

Trading Ideas

UCB and Biogen&#39;s Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

UCB SA

Press Releases

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

Earnings

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

Comments

UCB

UCB (UCBJY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga